Gamma interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates C1 inhibitor.

[1]  A. Wolkerstorfer,et al.  Scoring atopic dermatitis , 1998 .

[2]  D. Fraker,et al.  Fibrinolytic and Coagulant Responses to Regional Limb Perfusions of Tumor Necrosis Factor, Interferon-γ, and/or Melphalan , 1997, Thrombosis and Haemostasis.

[3]  A. Girbes,et al.  Augmented Procoagulant Activity in Cancer Patients, Treated with Recombinant Interferon-γ in Addition to Recombinant Tumor Necrosis Factor-α and Melphalan , 1996, Thrombosis and Haemostasis.

[4]  A. Schmaier,et al.  Phosphatase 2A participates in interferon-gamma's induced upregulation of C1 inhibitor mRNA expression. , 1996, Blood.

[5]  A. Szczeklik,et al.  Interferon‐gamma in the treatment of atopic dermatitis: influence on T‐cell activation , 1995, Allergy.

[6]  L. Huisman,et al.  On the Role of C1-Inhibitor as Inhibitor of Tissue-type Plasminogen Activator in Human Plasma , 1995, Thrombosis and Haemostasis.

[7]  A. Schmaier,et al.  Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor. , 1994, The Journal of laboratory and clinical medicine.

[8]  A. Schmaier,et al.  Expression of platelet C1 inhibitor , 1993 .

[9]  M. Boguniewicz,et al.  Recombinant interferon gamma therapy for atopic dermatitis. , 1993, Journal of the American Academy of Dermatology.

[10]  B. Wüthrich,et al.  Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  A. Kapp,et al.  The role of eosinophils in the pathogenesis of atopic dermatitis ‐ eosinophil granule proteins as markers of disease activity , 1993, Allergy.

[12]  E. Gelfand,et al.  Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. , 1992, The Journal of allergy and clinical immunology.

[13]  H. Ozer,et al.  Digital vasculitis associated with interferon therapy. , 1992, The American journal of medicine.

[14]  A. Szczeklik,et al.  Plasma fibrinolytic activity in healthy subjects with high and low lipoprotein(a) concentrations. , 1992, Thrombosis research.

[15]  M. Gyetko,et al.  Urokinase expression in mononuclear phagocytes: cytokine‐specific modulation by interferon‐γ and tumor necrosis factor‐α , 1992, Journal of leukocyte biology.

[16]  J. Soria,et al.  Effect of Interferon Gamma and Adriamycin on Fibrinolytic Activity Associated to Human Monocytes , 1992 .

[17]  W. Stüber,et al.  Determination of Human Prothrombin Activation Fragment 1+2 in Plasma with an Antibody against a Synthetic Peptide , 1991, Thrombosis and Haemostasis.

[18]  C. Scheibenbogen,et al.  Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. , 1990, Cancer research.

[19]  A. Schmaier,et al.  Interferon gamma increases in vitro and in vivo expression of C1 inhibitor , 1990 .

[20]  U. Reinhold,et al.  Recombinant interferon-γ in severe atopic dermatitis , 1990, The Lancet.

[21]  R. Geha,et al.  Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. , 1990, The American journal of medicine.

[22]  S. Lane,et al.  Immunoblotting of plasma in a pregnant patient with hereditary angioedema. , 1990, The Journal of laboratory and clinical medicine.

[23]  A. Schmaier,et al.  Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. , 1989, The Journal of biological chemistry.

[24]  J. Saurat,et al.  Scoring atopic dermatitis: the simpler the better? , 1989, Acta dermato-venereologica.

[25]  R. Strunk,et al.  Synovial fibroblast-like cells synthesize seven proteins of the complement system. , 1988, Arthritis and rheumatism.

[26]  J. Soria,et al.  Parallel induction of fibrinolysis and receptors for plasminogen and urokinase by interferon gamma on U937 cells. , 1988, Biochemical and biophysical research communications.

[27]  R. Schein,et al.  Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. , 1988, The Journal of laboratory and clinical medicine.

[28]  B. Robinson,et al.  Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease. , 1988, Thorax.

[29]  H. Pelzer,et al.  Determination of Human Thrombin-Antithrombin III Complex in Plasma with an Enzyme-Linked Immunosorbent Assay , 1988, Thrombosis and Haemostasis.

[30]  B. Zuraw,et al.  Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes. , 1987, Journal of immunology.

[31]  B. Bennett,et al.  Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. , 1987, Blood.

[32]  K. Whaley,et al.  Modulation of monocyte complement synthesis by interferons. , 1987, The Biochemical journal.

[33]  S. Gordon,et al.  Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone. , 1985, The Journal of clinical investigation.

[34]  A. Schmaier,et al.  High-molecular weight kininogen. A secreted platelet protein. , 1983, The Journal of clinical investigation.

[35]  R. Colman,et al.  Human High Molecular Weight Kininogen - A Secreted Platelet Coagulant Protein , 1981, Thrombosis and Haemostasis.

[36]  P. Black,et al.  Assay of effects of interferon on plasminogen activator. , 1981, Methods in enzymology.

[37]  P. Black,et al.  Interferon inhibits the release of plasminogen activator from SV3T3 cells , 1978, Nature.

[38]  T. Astrup,et al.  The fibrin plate method for estimating fibrinolytic activity. , 1952, Archives of biochemistry and biophysics.